Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States

Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, w...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	PharmacoEconomics Ročník 42; číslo 4; s. 447 - 461
Hlavní autori:	Brogan, Anita J., Davis, Ashley E., Mellott, Claire E., Fraysse, Jeremy, Metzner, Aimee A., Oglesby, Alan K.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Cham Springer International Publishing 01.04.2024 Springer Nature B.V
Predmet:	African Americans Antiretroviral drugs Cisgender Clinical trials Cost analysis Disease prevention Health Administration Health care industry Health Economics HIV Human immunodeficiency virus Immune system Infections Lifetime Medicine Medicine & Public Health Mutation Original Original Research Article Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Transgender persons United States > US
ISSN:	1170-7690, 1179-2027, 1179-2027
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!